177Lu标记低分子量PSMA靶向放射性药物治疗研究
本研究合成14种新型177Lu标记PSMA靶向放射性配体,在PSMA阳性前列腺癌模型中评估。177Lu-L1、L3、L5在单次111 MBq剂量下8周时显示肿瘤消退,其中177Lu-L1生存率最高,但尸检见泪腺和睾丸亚急性损伤,健康小鼠1年后未见放射性肾病。177Lu-L1因高肿瘤靶向性和低脱靶毒性成为临床候选。
要点
- 177Lu-L1在PSMA阳性肿瘤中摄取与177Lu-PSMA-617相当,8周时有效肿瘤消退且生存率最高。
- 单次111 MBq 177Lu-L1治疗8周后尸检见泪腺和睾丸亚急性损伤。
- 健康小鼠接受111 MBq 177Lu-L1后1年未观察到放射性肾病,可能与快速肾脏清除有关。
核心结论
- 177Lu-L1因高肿瘤靶向能力和低脱靶放射性毒性,是PSMA表达恶性肿瘤放射性核素治疗的可行临床候选。
研究设计与样本
- 研究合成14种新型PSMA靶向177Lu标记放射性配体(177Lu-L1至177Lu-L14),采用不同螯合剂和连接子。
- 体外使用人前列腺癌PSMA阳性PC3 PIP和PSMA阴性PC3 flu细胞及相应侧腹肿瘤模型评估。
- 单次给药111 MBq的177Lu-L1、177Lu-L3、177Lu-L5和177Lu-PSMA-617后8周评估疗效和毒性。
- 进一步研究177Lu-L1不同剂量疗效,并在健康免疫健全小鼠中确定长期毒性。
主要发现
- 放射性配体以高放射化学产率和纯度生产。
- 细胞摄取和内化显示仅在PSMA阳性PC3细胞中特异性摄取。
- 注射后72小时内,177Lu-L1、177Lu-L3和177Lu-L5在PSMA表达肿瘤中的摄取与177Lu-PSMA-617和177Lu-PSMA-I&T相当。
- 177Lu-L1、177Lu-L3和177Lu-L5在8周时显示有效肿瘤消退,其中177Lu-L1生存率最高。
- 治疗组8周尸检显示泪腺和睾丸亚急性损伤;健康小鼠接受111 MBq 177Lu-L1后1年未观察到放射性肾病,可能与快速肾脏清除有关。
临床怎么用
- 177Lu-L1可作为PSMA表达恶性肿瘤放射性核素治疗的临床候选药物进一步开发。
- 临床应用中需关注泪腺和睾丸的亚急性损伤风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop a prostate-specific membrane antigen (PSMA)-targeted radiotherapeutic for metastatic castration-resistant prostate cancer (mCRPC) with optimized efficacy and minimized toxicity employing the β-particle radiation of 177Lu. METHODS: We synthesized 14 new PSMA-targeted, 177Lu-labeled radioligands (177Lu-L1-177Lu-L14) using different chelating agents and linkers. We evaluated them in vitro using human prostate cancer PSMA(+) PC3 PIP and PSMA(-) PC3 flu cells and in corresponding flank tumor models. Efficacy and toxicity after 8 weeks were evaluated at a single administration of 111 MBq for 177Lu-L1, 177Lu-L3, 177Lu-L5 and 177Lu-PSMA-617. Efficacy of 177Lu-L1 was further investigated using different doses, and long-term toxicity was determined in healthy immunocompetent mice. RESULTS: Radioligands were produced in high radiochemical yield and purity. Cell uptake and internalization indicated specific uptake only in PSMA(+) PC3 cells. 177Lu-L1, 177Lu-L3 and 177Lu-L5 demonstrated comparable uptake to 177Lu-PSMA-617 and 177Lu-PSMA-I&T in PSMA-expressing tumors up to 72 h post-injection. 177Lu-L1, 177Lu-L3 and 177Lu-L5 also demonstrated efficient tumor regression at 8 weeks. 177Lu-L1 enabled the highest survival rate. Necropsy studies of the treated group at 8 weeks revealed subacute damage to lacrimal glands and testes. No radiation nephropathy was observed 1 year post-treatment in healthy mice receiving 111 MBq of 177Lu-L1, most likely related to the fast renal clearance of this agent. CONCLUSIONS: 177Lu-L1 is a viable clinical candidate for radionuclide therapy of PSMA-expressing malignancies because of its high tumor-targeting ability and low off-target radiotoxic effects.
引用
- Banerjee SR, Kumar V, Lisok A, et al. 177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. Eur J Nucl Med Mol Imaging. 2019. PMID: 31399803. doi:10.1007/s00259-019-04434-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。